FindTrial
Sign In

Capecitabine Dosage as a Prognostic Factor for the Development of Hand-Foot Syndrome

Capecitabine Dosage as a Prognostic Factor for the Development of Hand-Foot Syndrome

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20250419006
Enrollment
392
Registered
2025-04-19
Start date
2025-04-25
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients who were treated with capecitabine Cancer patients , capecitabine, hand-foot syndrome

Interventions

Cancer patients who were treated with capecitabine at the Division of Medical Oncology, Buddhasothorn Hospital
Prevention
Cancer patients

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Cancer patients who were planned to received at the first cycle of capecitabine-based chemotherapy regimen 2.Age > 18 years old

Exclusion criteria

Exclusion criteria: 1.Patients who received <2 cycles of capecitabine-based chemotherapy and were subsequently lost to follow-up

Design outcomes

Primary

MeasureTime frame
Hand-foot syndrome grade 2-3 after receiving capecitabine treatment CT-CAE version 5.0 grading for Hand foot syndrome—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Thailand

Contacts

Public ContactChaichana Chantharakhit

Buddhasothorn hospital

chaichana.md@gmail.com0817866945

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026